Company Filing History:
4 out of 854 
1 out of 328 
Years Active: 1998-2000
Title: Innovations and Contributions of Inventor Stephen John Pegg
Introduction
Stephen John Pegg is a notable inventor based in Macclesfield, GB, recognized for his significant contributions to the field of pharmaceuticals. With a portfolio consisting of four patents, Pegg has focused on the development of novel compounds with potential therapeutic applications.
Latest Patents
Among his latest inventions, Pegg's work on diastereomeric pure trifluoromethyl ketone peptide derivatives stands out. This inventive process pertains to pyrrolidine derivative compounds, particularly the compound (S)-1-[(S)-2-(4-methoxybenzamido)-3-methylbutyryl]-N-[(S)-2-methyl-1-(trifluoroacetyl)propyl]pyrrolidine-2-carboxamide, known by formula I. This compound serves as an inhibitor of human neutrophil elastase and shows promise in treating diseases such as emphysema and acute respiratory distress syndrome (ARDS). In addition, Pegg has also focused on quinazoline thymidylate synthase inhibitors, which include quinazoline derivatives and pharmaceutically acceptable salts that possess anti-tumor activity, highlighting his versatility in addressing various medical challenges.
Career Highlights
Pegg’s career has been marked by key roles in leading organizations. He has made impactful contributions while working at Zeneca Limited and British Technology Group Limited. His work in these companies has been pivotal in bringing new pharmaceutical innovations to the forefront.
Collaborations
Throughout his career, Pegg has collaborated with esteemed professionals in the field, including George Joseph Sependa and Elwyn Peter Davies. These collaborations have facilitated the exchange of ideas and fostered an environment of innovative thinking, ultimately leading to the development of his patents.
Conclusion
In summary, Stephen John Pegg has made notable advancements in pharmaceutical inventions, with a strong emphasis on therapeutic compounds that target critical medical issues. His patent portfolio reflects a commitment to innovation and improvement in healthcare through pharmaceutical research.